| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14656566.5.3.633 |
| P698 | PubMed publication ID | 15013931 |
| P2093 | author name string | John P Foreyt | |
| Walker S Carlos Poston | |||
| P2860 | cites work | Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines | Q47287928 |
| Effect of sibutramine on weight maintenance after weight loss: a randomised trial | Q33128832 | ||
| Economic costs of obesity and inactivity | Q33792165 | ||
| The discovery and status of sibutramine as an anti-obesity drug | Q34128195 | ||
| Influence of sibutramine on energy expenditure in African American women | Q43594329 | ||
| Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia | Q43722326 | ||
| Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors | Q43882700 | ||
| Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial | Q43882702 | ||
| Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy | Q43902773 | ||
| A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin | Q44262737 | ||
| Effects of Sibutramine on Binge Eating, Hunger, and Fullness in a Laboratory Human Feeding Paradigm | Q44436448 | ||
| National trends in antiobesity medication use. | Q44438332 | ||
| Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension | Q44498556 | ||
| One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial. | Q44563947 | ||
| Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials | Q44584072 | ||
| A Randomized, Double-blind, Placebo-Controlled Study of Sibutramine in the Treatment of Binge-Eating Disorder | Q44650361 | ||
| Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial | Q46704823 | ||
| Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus | Q47218179 | ||
| Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study | Q47218200 | ||
| Abuse liability assessment of sibutramine, a novel weight control agent | Q47247058 | ||
| Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine | Q47265863 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | (RS)-sibutramine | Q424151 |
| obesity | Q12174 | ||
| P304 | page(s) | 633-642 | |
| P577 | publication date | 2004-03-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Sibutramine and the management of obesity | |
| P478 | volume | 5 |
| Q35993474 | Antiobesity effect of Stellaria media against drug induced obesity in Swiss albino mice |
| Q37123715 | Behavioral management of obesity |
| Q35892373 | Clinical experience with dual action antidepressants in different chronic pain syndromes |
| Q38758765 | Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles |
| Q47273564 | NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine |
| Q64116647 | SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants |
| Q36536251 | The burden of type 2 diabetes: strategies to prevent or delay onset |
Search more.